Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center.

Jaime-Pérez JC, Gamboa-Alonso CM, Padilla-Medina JR, Jiménez-Castillo RA, Olguín-Ramírez LA, Gutiérrez-Aguirre CH, Cantú-Rodríguez OG, Gómez-Almaguer D.

Rev Bras Hematol Hemoter. 2017 Oct - Dec;39(4):325-330. doi: 10.1016/j.bjhh.2017.08.001. Epub 2017 Sep 14.

2.

Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County Hospital.

Yun HD, Dossul T, Bernal-Mizrachi L, Switchenko J, Ndibe C, Ibraheem A, Dixon MD, Langston AA, Nooka AK, Flowers CR, Pentz RD, Waller EK.

J Stem Cell Res Ther. 2016;6. pii: 328. doi: 10.4172/2157-7633.1000328. Epub 2016 Feb 19.

3.

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

Moskowitz AJ, Schöder H, Gavane S, Thoren KL, Fleisher M, Yahalom J, McCall SJ, Cadzin BR, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz SM, Kumar A, Matasar M, Ni A, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Straus D, Younes A, Zelenetz AD, Moskowitz CH.

Blood. 2017 Nov 16;130(20):2196-2203. doi: 10.1182/blood-2017-06-788877. Epub 2017 Sep 5.

PMID:
28874350
4.

New agents in relapsed/refractory Hodgkin's lymphoma.

Biasoli I, Spector N.

Rev Bras Hematol Hemoter. 2017 Jul - Sep;39(3):193-196. doi: 10.1016/j.bjhh.2017.05.003. Epub 2017 May 28. No abstract available.

5.

Role of Consolidative Radiation Therapy After Autologous Hematopoietic Cell Transplantation for the Treatment of Relapsed or Refractory Hodgkin Lymphoma.

Wilke C, Cao Q, Dusenbery KE, Bachanova V, Lazaryan A, Lee CK, Yuan J.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):94-102. doi: 10.1016/j.ijrobp.2017.05.007. Epub 2017 May 15.

PMID:
28816170
6.

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.

Karantanos T, Politikos I, Boussiotis VA.

Blood Lymphat Cancer. 2017;7:37-52. doi: 10.2147/BLCTT.S105458. Epub 2017 May 9.

7.

Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.

Bond DA, Alinari L.

J Blood Med. 2017 May 11;8:41-54. doi: 10.2147/JBM.S117452. eCollection 2017. Review.

8.

A Review of Autologous Stem Cell Transplantation in Lymphoma.

Zahid U, Akbar F, Amaraneni A, Husnain M, Chan O, Riaz IB, McBride A, Iftikhar A, Anwer F.

Curr Hematol Malig Rep. 2017 Jun;12(3):217-226. doi: 10.1007/s11899-017-0382-1. Review.

PMID:
28478586
9.

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma.

Mehrzad V, Ashrafi F, Farrashi AR, Pourmarjani R, Dehghani M, Shahsanaei A.

Adv Biomed Res. 2017 Mar 7;6:30. doi: 10.4103/2277-9175.201687. eCollection 2017.

10.

The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.

Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS.

Leuk Lymphoma. 2017 Nov;58(11):2705-2716. doi: 10.1080/10428194.2017.1306647. Epub 2017 Apr 10.

PMID:
28394191
11.

Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience.

Rimner A, Lovie S, Hsu M, Chelius M, Zhang Z, Chau K, Moskowitz AJ, Matasar M, Moskowitz CH, Yahalom J.

Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):1066-1076. doi: 10.1016/j.ijrobp.2017.01.222. Epub 2017 Feb 1.

PMID:
28332991
12.

Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era.

Hegerova L, Cao Q, Lazaryan A, McClune BL, Weisdorf DJ, Brunstein CG, Bachanova V.

Bone Marrow Transplant. 2017 May;52(5):697-703. doi: 10.1038/bmt.2016.357. Epub 2017 Jan 30.

13.

Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation.

Radford J, McKay P, Malladi R, Johnson R, Bloor A, Percival F, Sureda A, Peggs KS.

Bone Marrow Transplant. 2017 Mar;52(3):452-454. doi: 10.1038/bmt.2016.244. Epub 2017 Jan 16. No abstract available.

14.

A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.

Milgrom SA, Jauhari S, Plastaras JP, Nieto Y, Dabaja BS, Pinnix CC, Smith GL, Allen PK, Lukens JN, Maity A, Oki Y, Fanale MA, Nasta SD.

Cancer. 2017 Apr 15;123(8):1363-1371. doi: 10.1002/cncr.30482. Epub 2016 Dec 16.

15.
16.

Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective.

Reid RM, Baran A, Friedberg JW, Phillips GL 2nd, Liesveld JL, Becker MW, Wedow L, Barr PM, Milner LA.

Cancer Med. 2016 Nov;5(11):3059-3067. doi: 10.1002/cam4.879. Epub 2016 Oct 3.

17.

Treatment of relapsed and refractory Hodgkin Lymphoma.

von Tresckow B, Moskowitz CH.

Semin Hematol. 2016 Jul;53(3):180-5. doi: 10.1053/j.seminhematol.2016.05.010. Epub 2016 May 12. Review.

18.

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A.

Lancet Oncol. 2016 Sep;17(9):1283-94. doi: 10.1016/S1470-2045(16)30167-X. Epub 2016 Jul 20.

19.

Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation.

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy S, Thorsen L, Arbo I, Jones LW, Aakhus S, Lund MB, Kiserud CE.

Br J Cancer. 2016 Jul 12;115(2):178-87. doi: 10.1038/bjc.2016.180. Epub 2016 Jun 28.

20.

Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.

Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS.

Cancer. 2016 Sep 1;122(17):2680-8. doi: 10.1002/cncr.30100. Epub 2016 May 20.

Supplemental Content

Support Center